Journal
LEUKEMIA & LYMPHOMA
Volume 56, Issue 7, Pages 2039-2046Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2014.982645
Keywords
Diffuse large B-cell lymphoma; cell of origin; predictive marker; etoposide; R-CHOEP
Categories
Funding
- Department of Pathology, Herlev Hospital
- Dansk Kraeftforsknings Fond
- Roche A/S
Ask authors/readers for more resources
Addition of etoposide to the R-CHOP chemotherapy regimen with cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab (R-CHOEP) has resulted in improved survival in young patients with high-risk diffuse large B-cell lymphoma (DLBCL). It is not known whether biological factors can predict this effect. In this study, 245 patients representing all young patients with high-risk DLBCL treated with R-CHOP or R-CHOEP in 20042012 in Denmark were extracted from the Danish lymphoma database. Patients were stratified according to cell of origin (COO) into germinal-center B-cell-like (GCB) or non-GCB by Hans' algorithm. Only in patients with the GCB phenotype was treatment with R-CHOEP associated with improved progression-free survival (PFS) and overall survival (OS) compared with R-CHOP. Patients with GCB phenotype treated with R-CHOEP also had superior OS compared with patients with non-GCB phenotype treated with R-CHOER This was not seen in R-CHOP treated patients. This could suggest that R-CHOEP should be restricted to patients with GCB phenotype.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available